GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » 3-Year RORE %

Integra Lifesciences Holdings (Integra Lifesciences Holdings) 3-Year RORE % : -23.14% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Integra Lifesciences Holdings's 3-Year RORE % for the quarter that ended in Dec. 2023 was -23.14%.

The industry rank for Integra Lifesciences Holdings's 3-Year RORE % or its related term are showing as below:

IART's 3-Year RORE % is ranked worse than
70.65% of 804 companies
in the Medical Devices & Instruments industry
Industry Median: -4.37 vs IART: -23.14

Integra Lifesciences Holdings 3-Year RORE % Historical Data

The historical data trend for Integra Lifesciences Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings 3-Year RORE % Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.43 29.78 33.91 10.22 -23.14

Integra Lifesciences Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.22 1.09 -14.12 -22.89 -23.14

Competitive Comparison of Integra Lifesciences Holdings's 3-Year RORE %

For the Medical Devices subindustry, Integra Lifesciences Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's 3-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's 3-Year RORE % falls into.



Integra Lifesciences Holdings 3-Year RORE % Calculation

Integra Lifesciences Holdings's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.83-1.98 )/( 4.97-0 )
=-1.15/4.97
=-23.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


Integra Lifesciences Holdings  (NAS:IART) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Integra Lifesciences Holdings 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini officer: President & COO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Headlines

From GuruFocus